Patel inherits an FBI gripped by turmoil as the Justice Department has forced out a group of senior bureau officials in the ...

Indaptus Therapeutics, Inc. has received Clinical Trial Authorization from Health Canada ... Factors” included in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 ...

A federal judge on Thursday refused to temporarily block the Trump administration’s mass layoff of federal workers while a ...

Dynavax Technologies Corporation ( NASDAQ: DVAX) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Paul Cox - Vice President, Investor Relations & Corporate Communications Ryan Spencer - ...

Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively ...

The Senate voted to confirm Kash Patel as FBI director, a decision that places him atop the nation’s premier federal law ...

Trial decision follows unanticipated events of elevated unconjugated bilirubin levelsCompany advancing multiple next-generation PTH1R agonists ...

OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has entered into ...

Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company"), a clinical-stage biotechnology company pioneering innovative cancer and viral infection ...

today announced the Company has received Clinical Trial Authorization from Health Canada to initiate its clinical trial for its lead asset, Decoy20. This approval will allow the Company to expand ...

If the FDA follows an advisory committee’s vote, it can potentially be a transformative step in the delivery of mental health ...